Press release —
Sigrid Therapeutics CEO Sana Alajmovic selected to GEN's 2019 Top 10 Under 40
Stockholm, May 13, 2019. The leading international life science journal Genetic Engineering News (GEN) has selected Sana Alajmovic, CEO of Sigrid Therapeutics, to this year's highly prestigious Top 10 Under 40 list 2019. The names on the list are the result of an international search process to identify future leaders who currently work at a university, a company, a non-profit or a government agency. As CEO of a young life science company specializing in diabetes, Sana is one of five selected business leaders. Four of the other five come from academia while one divides her time between an academic institution and a non-profit organization in the healthcare sector.
"I am incredibly honored to be selected as one of the 10 upcoming leaders in the life science industry globally. I was 26 years old when I founded Sigrid together with Professor Tore Bengtsson. Our vision is to prevent disease and improve human health and I am proud of our team's focused and passionate work in taking our scientific discovery from the lab to the market. Our most advanced product candidate SiPore15™ targets people at risk of developing type 2 diabetes and is currently being evaluated in Finland and Sweden in a second clinical trial called STAR. We look forward to communicating the results of this study to researchers and investors in the third quarter of 2019," says Sana Alajmovic, Founder and CEO, Sigrid Therapeutics.
GEN's A-List of Upcoming Leaders can be found at: www.genengnews.com/a-lists/top-10-under-40-of-2019/
Topics
Categories
SIGRID is a Swedish consumer health company developing technologies designed to reduce the metabolic impact of modern meals. The company’s patented SiPore® technology works locally in the gastrointestinal tract by interacting with digestive enzymes involved in carbohydrate and fat digestion. By slowing nutrient breakdown during digestion, SiPore® supports steadier post-meal metabolic responses. SIGRID collaborates with clinicians, researchers, and health innovators to translate metabolic science into practical solutions supporting metabolic health, weight management, and glucose stability. The company was founded in 2014 and is headquartered in Stockholm, Sweden.
